Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aduhelm Approval Boosts Other Alzheimer’s Drug Developers

Even Companies Not Focused On Clearing Amyloid Benefitted

Executive Summary

Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.

You may also be interested in...



Lilly Braces For Impact Of CMS Draft Coverage Decision On Biogen’s Aduhelm

The draft national coverage determination, released shortly before Lilly CEO David Ricks spoke at the J.P. Morgan Healthcare Conference, said Medicare will cover anti-amyloid antibodies only for patients in clinical trials, severely limiting commercial potential for Biogen’s Aduhelm and near-term competitors.

Aduhelm May Not Be Perfect, But It May Be A Start – If Patients Can Access It

The Biogen/Eisai drug may have a disease-modifying impact on Alzheimer’s progression but the lack of published evidence is still causing prescriber reluctance and hampering reimbursement decisions.

IPO Update: Average Return Turns Negative For Newly Public Biopharma Firms

With 88 initial public offerings in the US through the end of the third quarter of 2021, the biopharma industry is two IPOs ahead of the full-year 2020 total, but with an average return of -4% momentum may slow.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel